Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative pharmaceutical products for the treatment of orphan mitochondrial and neuromuscular diseases.
In September 2015 our product, Raxone®, received European Marketing Authorization in the treatment of patients with LHON (Leber's Hereditary Optic Neuropathy). Raxone® is not only the first and only medicine approved for this condition, but it is also the first medicine approved for any mitochondrial disorder.
Raxone® is also investigated for the treatment of Duchenne Muscular Dystrophy (DMD) and Primary Progressive Multiple Sclerosis (PPMS). In addition, Santhera’s pipeline includes omigapil, an investigational drug with anti-apoptotic properties, a compound in development to address unmet medical needs for patients with Congenital Muscular Dystrophy (CMD).
In February 2018, Santhera obtained the worldwide, exclusive rights to develop and commercialize POL6014, an innovative macrocycle elastase inhibitor with the potential to treat Cystic Fibrosis and other Pulmonary Diseases.
For more information, please visit the company's website www.santhera.com